Product logins

Find logins to all Clarivate products below.


Aortic Repair Devices | Market Insights | Japan | 2021

Following the initial impact of the COVID-19 pandemic, the Japanese market for aortic repair devices will will expand at a modest rate, driven primarily by endovascular procedure volume growth and continued development and adoption of aortic stent grafts. However, endovascular procedure volume growth will be hindered to some extent by unavailability of certain aortic stent graft brands that are available in other established markets but not in Japan.

This Medtech 360 Report provides comprehensive data and analysis on the current state of the market for aortic repair devices in Japan across a 10-year period.

Related Medtech Insights Reports

Report
Structural Heart Closure Devices – Market Insights – Asia Pacific
The Asia Pacific structural heart closure device market will grow strongly overall through 2034, supported by rising AF prevalence, increasing physician confidence in structural heart interventions…
Report
Biosurgical Agents – Market Insights – Japan
The Japanese biosurgical agent market is projected to demonstrate a modest growth through 2034, driven by the rising volume of surgical procedures, increasing physician awareness of the clinical…
Report
Vascular Closure Devices – Market Insights – Global
The global VCD market will grow moderately, driven primarily by increasing endovascular interventional procedure volumes and by innovation associated with new products entering the market. Growth…
Report
Varicose Vein Treatment Devices – Market Insights – United States
The US varicose vein treatment device market will be driven by the continued shift toward minimally invasive procedures and the evolving reimbursement landscape supporting endovenous ablation and…
Report
Coronary Artery Bypass Graft Devices – Market Insights – United States
The US CABG device market will be supported by sustained demand for surgical revascularization in patients with increasingly complex CAD, where CABG remains the preferred treatment option…